Clinical Trials
36 trialsNCT06760702 2026-04-17
TEJAS-2
Aurigene Discovery Technologies Limited
Phase 2 Terminated
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT07072728 2026-03-03
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Psyence Australia Pty Ltd
Phase 2 Recruiting
NCT06962787 2025-11-17
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT05935748 2025-11-12
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
Phase 2 Terminated
NCT03175224 2025-06-27
SPARTA
Apollomics Inc.
Phase 2 Recruiting
NCT04383210 2025-04-03
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
Phase 2 Terminated
NCT04489771 2025-02-11
MK-6482-013
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT03634540 2024-12-20
MK-6482-003
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Active not recruiting
NCT06222125 2024-01-24
A Study of HB0025 Injection in Patients With Advanced Renal Cancer
Huabo Biopharm Co., Ltd.
Phase 2 Unknown
NCT03200717 2023-08-21
IO-PAZ
Novartis
Phase 2 Completed
NCT03428217 2023-03-20
CANTATA
Calithera Biosciences, Inc
Phase 2 Completed
NCT01545817 2019-10-09
CATChEz
Novartis
Phase 2 Terminated
NCT00896454 2018-10-17
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Amgen
Phase 2 Completed
NCT01482949 2018-06-27
A Rollover Protocol for Subjects Previously Treated With AGS-003
Argos Therapeutics
Phase 2 Terminated
NCT00498966 2018-02-05
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
AEterna Zentaris
Phase 2 Completed
NCT00835978 2017-05-30
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
Pfizer
Phase 2 Completed
NCT00423332 2017-02-02
Cediranib (AZD2171, RECENTINā¢) in Metastatic or Recurrent Renal Cell Carcinoma
AstraZeneca
Phase 2 Completed
NCT00903175 2016-11-08
RECORD-3
Novartis
Phase 2 Completed
NCT00618982 2015-12-24
Sorafenib Dose Escalation in Renal Cell Carcinoma
Bayer
Phase 2 Completed
NCT00422019 2015-04-10
A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma
Amgen
Phase 2 Completed
NCT00121420 2014-05-09
Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases
Pharmacyclics LLC.
Phase 2 Terminated
NCT00678119 2013-07-15
Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment
Argos Therapeutics
Phase 2 Completed
NCT00425035 2013-05-13
Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2
Amgen
Phase 2 Completed
NCT00082459 2012-09-07
Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma
Agenus Inc.
Phase 2 Terminated
NCT00282048 2012-07-31
Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
Pfizer
Phase 2 Completed
NCT00076011 2012-06-26
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
Pfizer
Phase 2 Completed
NCT00035243 2012-04-17
EPO906 Therapy in Patients With Advanced Kidney Cancer
Novartis
Phase 2 Completed
NCT00036036 2011-10-17
Study of CP-461 in Patients With Advanced Renal Cell Cancer
Astellas Pharma Inc
Phase 2 Completed
NCT00065572 2011-01-26
Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)
AstraZeneca
Phase 2 Suspended
NCT00101608 2010-03-02
Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Bristol-Myers Squibb
Phase 2 Completed
NCT00277316 2010-02-19
Study of XL999 in Patients With Metastatic Renal Cell Carcinoma
Symphony Evolution, Inc.
Phase 2 Terminated
NCT00740441 2009-09-25
A Phase II Study of AS1411 in Renal Cell Carcinoma
Antisoma Research
Phase 2 Unknown
NCT00059735 2008-03-05
A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma
Eisai Inc.
Phase 2 Completed
NCT00054886 2007-05-07
Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer
Pfizer
Phase 2 Completed
NCT00134186 2007-03-05
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
Pharmacyclics LLC.
Phase 2 Completed